American Society of Hirudotherapy

Resource Utilization and Cost Associated With Hand Trauma: An Analysis Outside of the Surgical Global Period

Retrospective study published in J Hand Surg (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical LiteratureHarirah et al. · The Journal of hand surgery, 2025

Abstract

PURPOSE: Hand injuries constitute approximately 20% of emergency department visits. Some of these injuries may require surgical care and extended follow-up outside of the global surgery period to obtain the best functional outcomes. However, little is known regarding national estimates of health care utilization outside of the global period and the characteristics and associated expenses of these services. METHODS: We conducted a retrospective, population-based analysis of patients using the Merative MarketScan Research Database between 2019 and 2022 for "treatment intense" hand trauma including distal radius fracture surgical treatment, flexor tendon repair, and replantation/revascularization. We evaluated health care utilization from 90 days to 1 year after the index operation and the associated payments and out-of-pocket expenses. RESULTS: There was a total of 20,141 patients identified from the database. Between 90 days and 1 year after the index procedure, 1,361 (6.8%) patients had at least one utilization visit while 18,780 (93.2%) patients had no utilization visits. This resulted in mean total payments of $934.31 for care from 91 to 365 days after the index operation, whereas mean out-of-pocket expenses were $89.89. Patients with at least one utilization visit were more likely to be older (51 vs 50 years), have a median household income between <40,000 to 60,000, and underwent treatment for a distal radius fracture or replantation. Additionally, flexor tendon repair was associated with a decreased adjusted mean of total insurance payments (odds ratio [OR], 0.57 [0.42-0.81]), compared to distal radius fracture fixation. CONCLUSIONS: Hand traumatic injuries are resource-intensive and may require treatment outside the global period to obtain the best functional outcomes. Findings from this study provide national estimates of the health care utilization outside of the global period and the associated costs to the health care systems and patients. TYPE OF STUDY/LEVEL OF EVIDENCE: Economic II.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHand InjuriesHealth ExpendituresHealth ResourcesEmergency Room VisitsRetrospective StudiesWrist FracturesPatient Acceptance of Health CareTendon InjuriesFingersHumansMaleFemaleAdultMiddle AgedAgedAdolescentYoung AdultUnited States

Summary

Population-based analysis of 20,141 patients with treatment-intense hand trauma found 6.8% had utilization visits 90 days to 1 year postoperatively, with mean total payments of $934.31 and replantation among predictors of utilization.

Context

This retrospective population-based study analyzed 20,141 patients with "treatment intense" hand trauma—including distal radius fracture fixation, flexor tendon repair, and replantation/revascularization—to quantify healthcare utilization and costs 90 days to 1 year after surgery, finding mean total payments of $934.31 and mean out-of-pocket expenses of $89.89. The abstract does not mention leeches, hirudotherapy, or the leech secretome, and the study focuses on economic analysis of post-surgical resource utilization rather than clinical management.

Citation

Reference (Vancouver style)

Harirah M, Basagaoglu B, Depani M, Chan PMP, Liu J, Yang DM, et al. Resource Utilization and Cost Associated With Hand Trauma: An Analysis Outside of the Surgical Global Period. J Hand Surg Am. 2025;50(10):1165-1173. doi:10.1016/j.jhsa.2025.06.017. PMID: 40815251

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.